| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -9,892,157 | -7,004,448 |
| Depreciation | 143,182 | 99,528 |
| Share-based compensation | 2,108,226 | 1,487,641 |
| Loss on disposal of assets | -169,291 | -167,103 |
| Change in fair value of related party note | 725,932 | 532,012 |
| Interest accrued on related party note | 74,722 | 49,722 |
| Prepaid expenses | 6,436 | 27,452 |
| Accounts payable | 959,305 | 577,453 |
| Accrued liabilities and other current liabilities | 136,939 | 84,280 |
| Other operating assets and liabilities | -1,729,554 | -1,124,067 |
| Net cash used in operating activities | -3,851,442 | -2,910,094 |
| Net proceeds from sale of equity | 13,137,498 | - |
| Proceeds from employee stock purchases and option exercises | 409,296 | 1,116 |
| Net cash provided by financing activities | 13,546,794 | 1,116 |
| Effect of exchange rate changes on cash | 8,820 | 13,853 |
| Net increase in cash and cash equivalents | 9,704,172 | -2,895,125 |
| Cash and cash equivalents at beginning of period | 4,577,040 | - |
| Cash and cash equivalents at end of period | 14,281,212 | - |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)